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Aluminium—related osteomalacia: response to reverse osmosis water
treatment. It is generally accepted that aluminium induces osteomalacia
in chronic hemodialysis patients by binding to the calcification front,
thereby inhibiting mineralization of osteoid. Because this form of
osteomalacia is vitamin D resistant, the condition has often been
assumed to be irreversible, although promising results have been
achieved recently by using a chelating agent for removal of aluminium
from the skeleton. In this paper we present four chronic hemodialysis
patients with aluminium toxicity and histologic osteomalacia in whom
the mineralization defect greatly regressed after the use of reverse
osmosis treated—water for dialysis, but without further treatment. In
three other patients, also with aluminium toxicity and histologic osteo-
malacia, similarly treated, the histological severity of the osteomalacia
remained static. Those patients in whom bone mineralization status
improved developed hyperparathyroidism after reverse osmosis water—
treatment, whereas the static patients remained euparathyroid. The
results suggest that resolution of alumium related osteomalacia may
occur with reduction in dialysis fluid aluminium, and that parathyroid
hormone plays a role in the healing of aluminium related osteomalacia.
The therapeutic implications are twofold: (1) attempts to remove all
traces of hyperparathyroidism may be detrimental to the bone miner-
alization status; and (2) stimulation of the parathyroid glands by means
of a mild reduction in dialysis fluid calcium may be of value in the
management of those cases with persistent osteomalacia and low bone
turnover.
Aluminium is now considered to be the prime factor in the
pathogenesis of dialysis osteomalacia affecting patients with
chronic renal failure [1—6]. The major soure of the aluminium
has been dialysis fluid [7—10], prepared directly from the do-
mestic water supply to which aluminium sulphate has been
added as a flocculating agent to remove brown particulate
matter. The aluminium binds to the calcification front [11—13]
where it appears to inhibit mineralization of osteoid, and
because skeletal uptake of calcium is blocked, there is a
tendency to hypercalcemia [5, 14] and relative hypoparathyroid-
ism. Because of low bone turnover and morbidity due to
aluminium related anemia [15] and neurotoxicity [16], it has
been assumed that the prognosis is poor, although recently
improvement in bone mineralization status has been reported
after removal of aluminium from the dialysis water by reverse
osmosis [14, 17, 18].
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In this paper we described seven chronic-hemodialysis pa-
tients with aluminium related osteomalacia who were subse-
quently provided with reverse osmosis facilities, but had no
other alteration in management. After three years, four patients
showed a marked improvement in bone mineralization, whereas
in the other three patients the skeletal pathology was un-
changed. These observations are discussed with reference to
the clinical, biochemical and bone histomorphometric findings.
Methods
Patients
Seven patients (4 males, 3 females, aged 29 to 64 years) with
advanced chronic renal failure of various etiologies were stud-
ied. These were all of the patients on dialysis in our unit who
had clinical or histological evidence of aluminium toxicity
before the introduction of reverse osmosis (RO) water—treat-
ment, and who had continued on dialysis for a sufficient
duration to enable assessment of the histological response to
the introduction of RO water treatment. The patients had
received regular hemodialysis at home or in the hospital for
between 11 and 78 months before acquisition of a reverse
osmosis (RO) unit, during which time all patients in group 1 and
patient 1 in group 2 used softened water, and patients 2 and 3 in
group 2 had no water treatment. The water supply to all patients
was treated with aluminium sulphate. Aluminium—containing
phosphate binders were prescribed if required to maintain
serum inorganic phosphate below 2 mmol/liter throughout the
period of observation and were continued during the period of
reverse osmosis water—treatment. All patients had histologic
evidence of osteomalacia associated with heavy deposition of
aluminium at calcified bone-osteoid interfaces. As a result of
the histologic findings in iliac crest bone biopsies obtained after
the use of reverse osmosis water—treatment for three years, the
patients were divided into group 1, comprising patients now
without histologic osteomalacia and one patient with much less
severe osteomalacia, and group 2 which consisted of three
patients with unchanged skeletal pathology. The groups were
compared using the Mann—Whitney U-test to determine any
differences in mean plasma—aluminium levels, serum biochem-
istry and bone histomorphometric indices either before or after
the use of reverse osmosis. This non-parametric statistical
model was employed because of the small sample size and
unknown distribution types [19].
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Table 1. Clinical and biochemical details of patients before RO water treatment
Patients
Age
yr
Serum/plasma biochemistry .
Dialysis fluid
aluminium
,amol/liter
Months
on dialysis
Calcium
mmol/liter
Phosphate
mmol/liter
APC
units/liter
PTH
pg/liter
Aluminium
mol/liter
Group 1
1 (JD) 24 2.70 1.90 80 0.86 12.8 NAC 34
2 (EW) 42 2.80 1.50 78 NAb 13.4 2.64 28
3 (iF) 47 3.00 1.52 96 2.40 5.1 0.52 47
4 (DM) 36 2.65 1.90 95 3.30 9.8 2.27 27
Group 2
I (AD) 59 2.99 1.77 99 0.26 8.1 NAC 15
2 (MH) 64 2.60 1.50 60 0.57 12.4 2.3 11
3(RS) 63 2.55 1.00 75 0.80 18.4 2.3 10
Normal range 2.16—2.62 0.80—1.40 <1.00 <0.60 — — —
PC < 0.03 NSd NS'1 0.05 NDd <0.03
a Alkaline phosphataseb Not available
C Statistical comparisons are for group 1 vs. group 2, by the U-test of Mann—Whitney
d Not significant
C These patients were commenced on reverse osmosis water treatment prior to measurement of dialysis fluid aluminium but mean water
aluminium for both patients was 7.1 mol/liter
Biochemistry
Plasma and dialysis fluid aluminium and serum levels of
calcium, inorganic phosphate and alkaline phosphatase (AP)
had been measured monthly in each patient prior to the use of
reverse osmosis and during the period of reverse osmosis
water—treatment and were expressed as mean pre-RO values.
Aluminium concentrations were estimated by means of electro-
thermal atomic—absorption spectrophotometry as described
previously [20]. Serum calcium, inorganic phosphate and alka-
line phosphatase were assayed by standard laboratory tech-
niques. Serum PTH was measured on a few occasions only,
around the times of the bone biopsies, by a double antibody
radioimmunoassay using rabbit anti-PTH serum directed pre-
dominantly against the N-terminal sequence of PTH.
Bone biopsies
Iliac crest bone biopsy—specimens were obtained from each
patient shortly before acquisition of a reverse osmosis unit and
after three years of water treatment. Pre-RO bone biopsies were
performed using a trephine bone—marrow needle providing a
core of bone 15 x 3 mm; post-RO transiliac bone biopsy
specimens (8 mm diameter) were obtained by the Meunier
needle. All biopsy specimens were fixed in 4% neutral
phosphate—buffered formaldehyde and embedded in methacryl-
ate; from each biopsy specimen thin (5 m) undecalcified
sections were cut on a Jung K sledge microtome. Three
representative sections from each biopsy specimen were
stained with Goidner's technique [21] for quantitative histology,
and from each of the post-RO biopsy specimens, the immedi-
ately adjacent sections were stained with toluidine blue for
estimation of the extent of surface osteoid bearing a calcifica-
tion front [22]. The "Aluminon" method [23] was utilized for
detection of aluminium.
By means of a semiautomatic method using the Graphic
Digitising System 1 equipment (Graphic Information Services
Ltd) which comprised a digitizing board with electronic cursor
linked to a microcomputer, a method broadly similar to that
employed by Malluche et al [24], the following histomorpho-
metric variables were measured for each biopsy: relative
osteoid volume (OV) [25], total osteoid surface (OS) [25], the
proportion of OS bearing a calcification front (CF) [22], active
osteoblastic surface (AOS) [251 and active resorption surface
(ARS) [26]. The width of the thickest osteoid seam was ex-
pressed as the maximum number of bright osteoid lamellae
(MNOL) visualized under polarised light.
The values obtained for OV, OS, CF and MNOL were
employed as indicators of the presence and severity of
osteomalacia. A diagnosis of osteomalacia was made in those
biopsy specimens with MNOL >4 and CF <60% [22]. The
values obtained for AOS and ARS were regarded as indices of
the degree of secondary hyperparathyroidism.
Results
Before the introduction of reverse osmosis
The patients of group 1 were younger and had been on
dialysis for longer than those of group 2 (Table 1). There was no
difference between the groups with regard to plasma and
dialysis fluid aluminium or serum levels of calcium, inorganic
phosphate and alkaline phosphatase. Serum PTH tended to be
higher in group 1. Dialysis fluid aluminium was high in four
patients, and likely to have been high in a further two patients
on the basis of very high water—aluminium. In one patient
(patient 3 of group 1) dialysis fluid aluminium was not high, but
he had been on dialysis for four years and dialysis fluid
aluminium measurements were available for only a few months
prior to the use of reverse osmosis. Fracturing osteodystrophy
was present in two patients in group 1, (fractured scapula and
ribs in patients 1 and 2) and one patient in group 2 (fractured
neck of femur and pubic ramus in patient 1). Patient 1 in group
2 also had dialysis encephalopathy and all patients except
patient 4 in group 1 had a microcytic anemia.
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Fig. 1. Bone histomorphometry indicating the
severity of osteomalacia and its response to RO
water treatment. Symbols are: (•) Group 1
patients, (0) group 2 patients. P statistical
comparisons are from group 1 vs. group 2 by the
Mann—Whitney U-test. Bars indicate the upper
limit of the normal range for relative osteoid
volume, maximum number of osteoid lamellae
(MNOL) and total osteoid surface. The lower
limit of the normal range for the extent of
calcification fronts along total osteoid surfaces is
indicated by the bar at 60%.
Fig. 2. Bone histomorphometry indicating the
degree of hyperparathyroidism before and after
RD water treatment. Symbols are: (•) Group 1
patients, (0) group 2 patients. P statistical
comparisons are from group 1 vs. group 2 by the
Mann—Whitney U-test. Bars indicate the upper
limit of the normal ranges.
Histologically, all seven patients had moderately severe
osteomalacia characterized by an increase in MNOL and OV,
there being no differences in these parameters between the two
groups (Fig. 1). A calcification front could not be detected by
toluidine blue in any of the biopsies. Whereas the mineraliza-
tion deficit was extensive in group 1 (OS > 48%), the patients in
group 2 had a more focal form of osteomalacia (OS < 32%). In
all cases, strongly positive Aluminon staining was demon-
strated along most of the length of the calcified bone—osteoid
interface. As well as osteomalacia, all seven patients had mild
osteitis fibrosa (hyperparathyroid bone disease), expressed as a
mild increase in active resorption surface with deep Howship's
lacunae and mild focal fibrosis not exceeding grade 2 [27];
active osteoblastic surfaces were increased in only two pa-
tients. The two groups did not differ in the degree of hyperpara-
thyroidism (Fig. 2).
After the introduction of reverse osmosis
With reverse osmosis water—treatment there was a significant
reduction in both plasma and dialysis fluid aluminium in both
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Table 2. Clinical and biochemical details of patients after RO water treatment
Age
Serum/plasma biochemistry •Dialysis fluid
aluminiumCalcium Phosphate AP PTH Aluminium
Patients yr mmol/liter mmol/liter units/liter pg/liter pinol/liter pinol/liter
Group 1
I (JD) 27 2.33 1.62 125 1.50 6.3 1.18
2 (EW) 45 2.35 1.80 138 2.30 3.4 0.33
3 (JF) 50 2.83 1.64 239 2.70 5.0 0.6
4 (DM) 39 2.70 2.78 180 2.60 8.3 0.54
Group 2
I (AD) 62 2.67 0.90 60 0.34 6.3 0.6
2 (MH) 67 2.30 1.60 64 0.58 7.3 0.4
3 (RS) 66 2.38 1.23 71 0.47 5.5 0.4
Normal range — 2.16—2.62 0.80—1.40 <100 <0.60 — —
P" NS <0.03 <0.03 <0.03 NSC
O Alkaline phosphataseb Statistical comparisons are for group 1 vs. group 2, by the U-test of Mann-Whitney
C Not significant
groups, and there was again no difference between the groups.
However, the plasma aluminium remained significantly ele-
vated in most patients. The serum calcium was similar in both
groups, but the serum phosphate in the patients of group 1 was
significantly greater than in those of group 2. The patients of
group 1 exhibited biochemical evidence of hyperparathyroidism
with elevated serum levels of alkaline phosphatase and PTH
whereas those in group 2 did not; the differences were signifi-
cant (Table 2).
Healing of fractures occurred in all patients with fracturing
bone disease before the introduction of reverse osmosis and no
patient developed new fractures. This was accompanied by
resolution of microcytosis and improvement in anemia, but
patient 1 in group 2 subsequently died of dialysis encephalop-
athy.
Histologically, three of the patients in group 1 no longer had
osteomalacia (MNOL <5, CF >60%) and the fourth patient
showed substantial improvement in bone mineralization, with
reduction in OV from 21.2% to 11.4% and reduction of MNOL
from 9 to 6 (Fig. 1). By contrast, the degree of osteomalacia
affecting those patients of group 2 was unchanged with respect
to the previous biopsies. In six patients, weakly—positive
Aluminon staining was distributed focally along the length of
the calcified bone—osteoid interface and occasionally at cement
lines within calcified bone; in the seventh patient (from group 1)
aluminium could not be shown histochemically. After reverse
osmosis water—treatment the patients in group 1 had more
advanced osteitis fibrosa reflected histomorphometrically by
significantly—increased active resorption and active osteoblastic
surfaces, whereas in group 2 the degree of osteitis fibrosa
remained mild (Fig. 2).
Discussion
Although the studies of McClure et al [26, 281 indicate that
introduction of RO water treatment was associated with an
improvement in bone mineralization status, they do not specif-
ically refer to the progress of individual patients. Leather et al
[17] reported that fractures in their renal osteodystrophy cases
usually healed following the use of a deionizer to prepare the
dialysis fluid, but they did not include bone histology in their
study. While the mineralization defect eventually resolved in
one of the patients of Boyce et a! [141 with aluminium related
osteomalacia after removal from exposure to aluminium, one of
the two patients with fracturing osteomalacia reported by
Brown et al [181 failed to respond to RO water purification
alone, although was later successfully treated by desfer-
rioxamine.
Our results indicate that, while a good clinical response with
healing of fractures may occur following the introduction of RO
water treatment, this is not always accompanied by histological
resolution of osteomalacia. Patients with a good histological
repsonse could not be distinguished on the basis of bone
histology or routine serum biochemistry before the use of RO
water treatment. Both groups had been exposed to high levels
of aluminium in the dialysis fluid with very high plasma—
aluminium levels which were similar in both groups. Following
the introduction of RO water treatment the dialysis fluid
aluminium was maintained at a low level in both groups and
there was a significant fall in plasma aluminium. However, the
plasma aluminium remained significantly elevated in most pa-
tients and was higher than we would expect to result from the
continuation of small doses of aluminium—containing phosphate
binding agents. This response confirms our previous observa-
tion that the plasma aluminium falls only slowly following
reduction in exposure to aluminium, presumably as a result of
poor clearance during hemodialysis and relatively slow uptake
by tissues [291.
We did not assess the bone apposition rate in our patients
using double tetracycline labelling, but there was a marked rise
in the percentage of osteoid seams bearing a calcification front
in all patients with RO water treatment, the rise being signifi-
cantly higher in patients in group 1. This, together with the
striking reduction in indices of osteoid bone volume in the
patients in group 1, despite increased bone turnover, is strong
indirect evidence that there was an improvement in bone
mineralization.
The main distinguishing feature of the patients with a good
histological response to RO water treatment was that they
tended to have higher serum PTH levels. It is interesting to note
that they were younger and had been on hemodialysis for longer
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than the nonresponders, While aluminium appears to suppress
parathyroid hormone release [301 there is currently no evidence
that the element can inhibit the development of parathyroid
hyperplasia, and the parathyroid glands of the responders,
exposed to abnormal mineral biochemistry for longer periods of
time than the nonresponders, have had more opportunity to
develop hyperplasia. After the introduction of RO units, those
patients with persistent osteomalacia remained biochemically
euparathyroid and only had mild osteitis fibrosa, whereas the
responders developed biochemical and histologic evidence of
hyperparathyroidism consistent with removal of aluminium—
mediated suppression of PTH release from already hyperplastic
glands. Furthermore, the results suggest that PTH could be
involved in the restoration of mineralization in "paralyzed"
osteoid seams, possible through the genesis of matrix vesicles
by PTH-activated osteoblasts. Although it is likely that matrix
vesicles are not involved in mineralization of lamellar bone
under normal circumstances [31], Anderson et al [321 identified
matrix vesicles and associated tiny clusters of apatite—like
material in osteoid seams subjacent to active osteoblasts in six
out of seven patients with renal osteodystrophy. While calcium
hydroxyapatite crystal formation at the calcification front ap-
pears to be blocked by aluminium [11—13], possibly acting as a
crystal poison [33], matrix vesicles derived from osteoblasts
reactivated by high PTH levels could serve to nucleate a new
calcification front in the osteoid seam superficial to the
aluminium—saturated calcified bone—osteoid interface, with sub-
sequent mineralization of the seam. This mechanism of bypass-
ing the aluminium barrier is not available to euparathyroid
patients whose inactive osteoblasts were unable to provide
matrix vesicles. While the similar aluminium staining on our
two groups after RO water treatment may simply reflect quan-
titative limitations of the staining method, this might also be
explained by PTH-induced mineralization in a new calcification
front. This hypothesis is consistent with the observation by
Cournot—Witmer et al [12] that moderate to severe hyperpara-
thyroidism appeared to protect against osteomalacia despite the
fact that the bone aluminium levels in hemodialysis patients
with osteitis fibrosa did not differ significantly from those with
osteomalacia. Unfortunately we did not have bone aluminium
measurements in our patients and so were unable to substanti-
ate this observation. There is strong circumstantial evidence for
a role of relative hypoparathyroidism in the pathogenesis of
aluminium related osteomalacia [6, 12, 34, 351, and the occur-
rence of osteomalacia after parathyroidectomy further supports
the role of PTH in maintaining bone mineralization in uremia
[36]. Although it has been implied that the protective effect of
high serum PTH levels is mediated via high bone turnover with
dilution of the bone surface aluminium—concentration [3], we
consider this hypothesis unlikely because the two groups of
patients in our study did not differ in plasma aluminium levels
or, by assumption, in aluminium levels at the bone surface. In
addition, bone aluminium staining after RO water treatment
was similar in both groups.
After RO water purification, the group in which the bone
mineralization status improved had higher serum levels of
inorganic phosphate than the group with static bone pathology.
Despite there being no difference in serum calcium between the
groups it is possible that the hyperphosphatemia may have
contributed to parathyroid overactivity [37]. However, even if
inorganic phosphate were not involved in the genesis of post-
RO hyperparathyroidism, the presence of raised serum, and
therefore extracellular fluid levels would augment the calcium—
phosphate ion product in osteoid and counteract any possible
localized phosphate depleting effect of aluminium [38, 39].
Two main points emerge from this study. First, aluminium
related osteomalacia may persist in chronic hemodialysis pa-
tients with low bone turnover despite a large reduction in
plasma aluminium. Although it is good policy to attempt to keep
serum inorganic phosphate within reasonable limits to prevent
metastatic calcification in soft tissue [40], we consider it possi-
bly detrimental to the bone mineralization status to manipulate
serum levels of calcium and inorganic phosphate or to perform
parathyroidectomy in order to remove all traces of hyperpara-
thyroidism. Although it is generally accepted that osteomalacia
is the crippling form of renal osteodystrophy, in our experience
mild to moderate osteitis fibrosa is rarely symptomatic and
therefore is clinically acceptable.
Secondly, aluminium related osteomalacia will respond to
RO water treatment alone, but a good histological response
occurs only in the presence of hyperparathyroidism. In those
cases with persistent osteomalacia and low bone turnover, a
mild reduction in dialysis fluid calcium with the aim of stimu-
lating the parathyroid glands may offer a useful adjunct or
alternative to desferrioxamine in the management of this dis-
tressing disease.
Reprint requests to Dr. G.D. Smith, Department of Pathology,
Stobhill General Hospital, Glasgow G21 3UW, United Kingdom.
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